Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04577755 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pomalidomide Treatment in Patients With Kaposi Sarcoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Oct 1, 2026 → Feb 4, 2027
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 65 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 1, 2026 to Feb 4, 2027 Eligibility criteria expanded, about 11 words · Study description revised · Site details revised at 3 of 15 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Study description revised
    • Site details revised at 3 of 15 sites
  2. Re-verified, no change to tracked fieldsv64
  3. Study description expanded, about 59 wordsv63 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (15)v62 See this version in full on ClinicalTrials.gov ↗
  5. 9 versions Re-verified since Sep 2, 2025, no change to tracked fieldsv53-v61
Show 37 earlier versionsHide 37 earlier versions
  1. Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Pomalidomide (Drug), X-Ray Imaging (Procedure) to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Pomalidomide (Drug), X-Ray Imaging…v52
  2. Re-verified, no change to tracked fieldsv51
  3. Primary and study completion dates: Mar 1, 2026 to Oct 1, 2026 Trial status: Recruiting to Active, Not Recruiting · Site details revised at 15 of 15 sitesv50 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 15 of 15 sites
  4. Site details revised at 1 of 15 sitesv49
  5. Re-verified, no change to tracked fieldsv48
  6. Eligibility criteria expanded, about 83 words Study description shortened, about 44 wordsv47 Show 1 more changeShow less
    • Study description shortened, about 44 words

    See this version in full on ClinicalTrials.gov ↗

  7. Re-verified, no change to tracked fieldsv46
  8. Site contacts updated at 1 of 15 sitesv45
  9. Site details revised at 1 of 15 sitesv44
  10. Re-verified, no change to tracked fieldsv43
  11. Site contacts updated at 1 of 15 sitesv42
  12. Site contacts updated at 1 of 15 sitesv41
  13. Site details revised at 1 of 15 sitesv40
  14. Study sites: 14 to 15v39
  15. Site details revised at 1 of 14 sitesv38
  16. Re-verified, no change to tracked fieldsv37
  17. Site details revised at 1 of 14 sitesv36
  18. Re-verified, no change to tracked fieldsv35
  19. Study sites: 13 to 14v34
  20. Site details revised at 1 of 13 sitesv33
  21. Re-verified, no change to tracked fieldsv32
  22. Site details revised at 1 of 13 sitesv31
  23. Site details revised at 1 of 13 sitesv30
  24. Site details revised at 1 of 13 sitesv29
  25. Site details revised at 1 of 13 sitesv28
  26. Site details revised at 1 of 13 sitesv27
  27. Re-verified, no change to tracked fieldsv26
  28. Start date: Jul 1, 2021 to Mar 18, 2022 Interventions: Pomalidomide (Drug) to Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Pomalidomide (Drug), X-Ray Imaging (Procedure)v25 Show 1 more changeShow less
    • Interventions: Pomalidomide (Drug) to Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Pomalidomide (Drug), X-Ray Imaging (Procedure)
  29. Site contacts updated at 1 of 13 sitesv24
  30. Study sites: 12 to 13v23
  31. Primary and study completion dates: Sep 30, 2025 to Mar 1, 2026 Start date: Mar 30, 2022 to Jul 1, 2021v22 Show 1 more changeShow less
    • Start date: Mar 30, 2022 to Jul 1, 2021
  32. Study sites: 7 to 12v21
  33. Study sites: 4 to 7v20
  34. Re-verified, no change to tracked fieldsv19
  35. Study sites: 3 to 4v18
  36. Study Status, Contacts/Locationsv17
  37. Start date: Jul 1, 2021 to Mar 30, 2022v16
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
Trial Details
NCT Number NCT04577755
Lead Sponsor National Cancer Institute (NCI)
Conditions Skin Kaposi Sarcoma
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov